# Mario Family Funds

> Mario Family Funds is a VC fund in Chatham backing Biotechnology and Medical. See 3 investments, check sizes, portfolio and contact details. Updated Sep 2026.

- Type: VC Fund
- Location: Chatham, United States
- Total investments: 3
- Last investment: Mar 2018
- Lead investor: 0%
- Last updated: Sep 2026
- Website: http://mariofamily.com

Mario Family Funds is an investment fund focused on biotechnology companies.

## Contacts

5 contacts available for Mario Family Funds. Shizune tracks 1 team members at Mario Family Funds. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/mario-family-funds?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 100% |
| Medical | 2 | 67% |
| Women's | 1 | 33% |
| Robotics | 1 | 33% |
| Health Care | 1 | 33% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |
| Venture - Series Unknown | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jeremy Mario | Managing Partner | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Clinipace | Clinipace is a clinical research organization that specializes in fully integrated clinical research services for biopharmaceutical and medical device firms. It delivers a level of collaboration and flexibility not possible in a traditional CRO environment. The company was founded in 2003 and headquartered in Morrisville, North Carolina. | $19.9M | Venture - Series Unknown | Mar 28, 2018 |  |
| OrphoMed | OrphoMed is a San Francisco Bay Area pharmaceutical company focused on the development of novel first-in-class therapeutic dimer conjugates based on its proprietary DIMERx™ platform technology. The company is leveraging its DIMERx™ technology to address the problem of visceral hypersensitivity and pancreatitis in the treatment of gastrointestinaldisorders and the unmet medical needs in the treatment of both peripheral neuropathic and systemic nociceptive pain.The lead candidate ORP-101 is a peripherally acting sodium ion channel blocker (Nav 1.7), mu agonist/kappa antagonist dimer. The molecule does not cross the blood brain barrier and, unlike other opioids that constrict the sphincter of Oddi, ORP-101, when given intravenously in animal studies, has instead been shown to relax the sphincter. The former attribute implies no abuse potential and the latter minimizes the risks of pancreatitis and/or abdominal pain related to sphincter of Oddi constriction. These two attributes, in combination with the well-understood pharmacology of ORP-101, make the molecule a suitable candidate for chronic treatment of conditions associated with visceral and somatic hypersensitivity and hyperalgesia. Therefore we have positioned ORP-101 for two non-overlapping indications: the oral form for colonic hyperalgesia and gastric dysmotility in IBS-D and the parenteral form for the treatment of peripheral neuropathic pain. The potential clinical benefits are backed by compelling data from validated animal models.The company is also developing potent non-opioid and opioid conjugates to treat acute and chronic nociceptive pain. The non-opioid analgesic conjugate is designed to be non-ulcerogenic and liver-safe and, therefore, has the potential to reshape the pain market served by acetaminophen and NSAIDs. Similarly, the opioid conjugate is designed to be orally active and have a lower potential for dependence than currently available opioids.DIMERx™ technology results in conjugates designed to preserve the receptor pharmacology of their individual constituents, but to have therapeutic profiles well suited for different clinical indications. The components of the conjugates have all been previously proven to be safe and effective for other indications and, therefore, the conjugates have reduced developmental risks. The DIMERx™ conjugates are considered to be new molecular entities and have composition of matter intellectual property protection. | $39M | Series A | May 24, 2017 |  |
| Femasys | Femasys is a biomedical company focused on transforming women’s healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patientcare and health economics: FemBloc, a first and only non-surgical product for permanent birth control and FemaSeed, a first and only directed sperm delivery product for infertility treatment. Femasys’ FemVue product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician’s office setting. | $10.2M | Series B | Apr 29, 2015 |  |

3 of 3 investments shown.

## Co-investors
- [Crestline](https://shizune.co/investors/profile/crestline) — VC Fund, 1 deal together
- Emergent Growth Fund — VC Fund, 1 deal together
- [Harbert Growth Partners](https://shizune.co/investors/profile/harbert-growth-partners) — VC Fund, 1 deal together
- [Harbert Management Corporation](https://shizune.co/investors/profile/harbert-management-corporation) — VC Fund, 1 deal together
- [Hatteras Venture Partners](https://shizune.co/investors/profile/hatteras-venture-partners) — VC Fund, 1 deal together
- Legacy Capital Partners — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Mario Family Funds invest in?

Mario Family Funds invests primarily in Biotechnology, Medical and Women's startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Mario Family Funds?

Public channels for Mario Family Funds include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Mario Family Funds?

The team at Mario Family Funds includes Jeremy Mario (Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co